Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Tomoko Smyth, Yoko Nakatsuru, Ryoto Fujita, George Ward, Luke Bevan, Jon Lewis, Nicola Wallis and John Lyons | ||||||||||||
Title | The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo | ||||||||||||
|
|||||||||||||
URL | http://cancerres.aacrjournals.org/content/76/14_Supplement/1287 | ||||||||||||
Abstract Text | Cancer Res 2016;76(14 Suppl):Abstract nr 1287 |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ASTX-660 | ASTX660|ASTX 660 | SMAC Mimetic 8 | ASTX-660 is a SMAC mimetic that inhibits cIAP and XIAP, potentially resulting in tumor cell death (Cancer Res 2016;76(14 Suppl):Abstract nr 1287, PMID: 31900279). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|